Browse News
Filter News
Found 73 articles
-
Alexion Canada Appoints Karen Heim as New General Manager
4/2/2024
Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
-
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
3/16/2024
Labcorp, a global leader of innovative and comprehensive laboratory services, presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer.
-
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
12/5/2023
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer.
-
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
9/28/2023
ImmunoGen Inc. announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer.
-
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
7/31/2023
ImmunoGen, Inc. announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen.
-
Flash Therapeutics Appoints Jérôme Bédier as President to Accelerate its Biopharmaceutical CDMO Business Development
7/6/2023
Flash Therapeutics, the French specialist in the design and bioproduction of lentiviral vectors for the transfer of DNA and RNA genetic material for its biotech customers in gene, cell, RNA and vaccine therapies, today announced the appointment of Jérôme Bédier as President.
-
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
6/4/2023
ImmunoGen Inc. announced detailed results from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer.
-
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
5/24/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio.
-
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
5/3/2023
ImmunoGen Inc. (Nasdaq: IMGN) today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
-
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
4/28/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
-
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
3/25/2023
ImmunoGen, Inc. announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the SGO 2023 Annual Meeting in Tampa, Florida.
-
ImmunoGen Reports Recent Progress and 2022 Financial Results
3/1/2023
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2022.
-
The FDA has a number of PDUFA dates for the remainder of November for Spectrum, ImmunoGen, Scynexis and Y-mAbs.
-
ImmunoGen's Elahere was approved Monday under the FDA's accelerated pathway for patients who have received one to three previous lines of systemic therapy.
-
Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
11/14/2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying epithelial ovarian cancer (EOC) patients who are eligible for targeted treatment with ELAHERE™ (mirvetuximab soravtansine-gynx).
-
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
11/14/2022
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
-
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
11/4/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.
-
ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
10/28/2022
ImmunoGen, Inc. today announced findings from a retrospective pooled analysis of patients who achieved extended treatment benefit (ETB) with mirvetuximab soravtansine (mirvetuximab) monotherapy across three clinical trials in folate receptor alpha (FRα)–positive recurrent ovarian cancer.
-
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
9/29/2022
ImmunoGen, Inc. today announced several data presentations for mirvetuximab soravtansine (mirvetuximab) at the 2022 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in New York City.
-
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
9/11/2022
ImmunoGen, Inc. announced findings from an analysis of patient-reported outcomes with mirvetuximab soravtansine versus chemotherapy in the randomized Phase 3 FORWARD I study in platinum-resistant ovarian cancer.